February 1, 2022 7:50am
Without volatility there would be no trading opportunities, no traders or a need for algorithms
Pre-open indications: 10 SELLs and 1 PUMP/PROMOTE
What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Only the facts …
Dow futures are DOWN -0.12% (-42 points), S&P futures are DOWN -0.09% (-4 points) and NASDAQ futures are UP +0.16% (+24 points)
Stock futures were mixed and lower Tuesday morning,
European markets advanced as markets kicked off a new month of trading,
Asia-Pacific markets rose, markets in mainland China, Hong Kong, South Korea and Singapore are closed for a holiday.
Economic Data Docket: the ISM manufacturing report and the latest labor market view from the Job Openings and Labor Turnover Survey, both out at 10 a.m. ET.
Henry’omics:
Following a terrible January month for the cell and gene therapy sector …
Very interesting quote attributed to myself from yesterday, “wipe the slate clean, SELL into Strength after closing with strong gains Friday. Last session “standing” for January as algorithms wait in reserve to “rule” a downslide in fear of upcoming earnings’ reporting
If you didn’t remember what happen at Monday’s close, you won’t be prepared for today’s session:
RegMed Investors’ (RMi) closing bell: “I said, take the highs and sell them, there’s always a question of how long the upsides will last. The algorithms will be lurking that’s; why this a.m., I wrote to “sell into strength” to take profits” … https://www.regmedinvestors.com/articles/12279
Ebb and flow –
February begins today
January stats: 1 holiday, 1 neutral, 13 negative and 6 positive closes
Companies in my headlights – It’s your decision; I provide an idea and context:
Probabilities/ Potentials pre-open share pricing indication moves:
Maintaining SELL into Strength:
Alnylam Pharmaceuticals (ALNY) closed up +$5.51 to $137.60 after Friday’s +$4.91, Thursday’s $2.94 and Wednesday’s -$0.82 to $130.12 and last Tuesday’s -$5.59 with NO pre-open indication
Applied Genetic Technologies (AGTC) closed up +$0.05 to $1.95 after Friday’s +$0.33 to $1.90 after Thursday’s $1.57, Wednesday’s $1.66 and last Tuesday’s $1.69 with a negative -$0.07 or -3.59% pre-open indication. +$0.38 upside in two (2) sessions for a long-suffering equity – run until real news or management change.
BioLife Solutions (BLFS) closed up +$2.34 to $29.84 after Friday’s +$1.51 after Thursday’s -$1.69, Wednesday’s -$0.32 and Tuesday’s -$1.11 to $28.00 with a negative -$3.84 or -12.87% pre-open indication.
Fate Therapeutics (FATE) closed up +$4.88 to $41.51 after Friday’s +$0.85, Thursday’s -$3.49, Wednesday’s -$0.60 and last Tuesday’s +$0.35 with a positive +$0.49 or +1.18% preopen indication.
Global Blood Therapeutics (GBT) closed up +$1.43 to $28.85 after Friday’s +$1.74, Thursday’s -$0.83, Wednesday’s -$0.32 and Tuesday’s -$0.83 with a negative -$0.10 or -0.35% pre-open indication.
Intellia Therapeutics (NTLA) closed up +$8.55 to $94.57 after Friday’s +$3.62 to $86.02, Thursday’s -$2.82 to $82.40, Wednesday’s $85.22, Tuesday’s $84.77 with a negative -$0.57 or -0.60% pre-open indication. That’s +$10.17 in two (2) sessions.
CRISPR Therapeutics (CRSP) closed up +$4.75 to $63.75 after Friday’s +$0.24 to $59.00, Thursday’s -$3.08 to $58.76, Wednesday’s $61.84 and last Tuesday’s $62.54 with a positive +$0.19 or +0.30% pre-open indication. +$8.07 in three (3) sessions.
Editas Medicine (EDIT) closed up +$1.61 to $19.04 after Friday’s +$0.01 to $17.43, Thursday’s $17.41, Wednesday’s $17.81 and last Tuesday’s $18.23 with a positive +$0.06 or +0.32% pre-open indication. That’s +$1.62 in two (2) sessions.
Ultragenyx Pharmaceuticals (RARE) closed up +$3.93 to $69.93 after Friday’s +$1.67, Thursday’s $3.78, Wednesday’s -$0.96 and last Tuesday’s +$1.11 with NO pre-open indications.
Vericel (VCEL) closed up +$2.30 to $35.58 after Friday’s +$1.59 to $33.28 after Thursday’s -$1.28 to $31.69, Wednesday’s $32.97, Tuesday’s $33.60 and last Monday’s $33.93 with a positive +$0.71 or +0.32% pre-open indication. That’s +$3.89 in two (2) sessions.
Pump and Promote:
Biostage (OTCQB: BSTG) closed flat with 11 shares traded after Friday’s +$0.05 to $3.90 with 3,362 shares traded, Thursday’s +$0.24 to $3.85 with 10,073 shares traded, Wednesday’s -$0.00 with 7,796 shares traded after Tuesday’s +$0.31 with 2,794 shares traded.
- WHO is BUYING these shares of a company with a 2-year-old IND and NO clinical trial initiation?
- Just another example of a game of “fake it because they can’t make it?
- Overhang of non-registered PPM shares is also a factor before ANY offering to be proposed?
- Last week’s news re terminal death suit: The Court granted BSTG's motion for a preliminary injunction and held that Medmarc breached its duty to defend the Company when it unilaterally stopped paying for the defense. The Court expressly stated that Medmarc engaged in "unlawful conduct" by unilaterally terminating the defense. Although the coverage dispute remains pending between the parties, the Court held that "Medmarc will mostly likely lose its claim" seeking to terminate the payment of the defense, and therefore, it must continue to pay the defense until the coverage dispute is resolved.”
- It’s NOT over, the terminal death law suit still HANGS over the company.
The BOTTOM LINE: reiterating, “Investors should remain cautious, but also prepare for new buying opportunities” even after a dramatic and volatile Frida and Monday.
I believe the “hits” will be forthcoming…
After several ups and downs, the Nasdaq closed with strong price gains Monday after Friday’s although volume fell slightly.
- Monday - Sector volume was HIGH with 15 of the 32-upside having higher than the 3-month average volume with NADA volume of 1 of 1-downside having higher than the 3-month average volume;
- Friday - Sector volume was LOW with 9 of the 30-upside having higher than the 3-month average volume with LOW volume of 1 of 4-downside having higher than the 3-month average volume
MY real question is which stock’s share pricing rise is sustainable?
Pay attention to volatility, most times the effect of dramatic upside moves after multiple downsides weekly “plays” could end-up being sold into strength – in my view.
The cell and gene therapy sector has been oversold for most of the month of January and as February starts so does earnings’ reporting – thus more declines are in-store.
Investors should focus on forward-looking guidance, last year’s operating losses i.e., spending and cash positions or runways!
I am NOT changing my position, “Brace for more choppiness as we move further into the month and the beginning of Q1/22 waiting for Q4 and end-of-year numbers”.
- I say today what others won't, so you can do what others can't whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors
So, my bottom of the Bottom Line, Investors should be extremely cautious about adding any new exposure.
- RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
WHY do I keep reporting on Biostage (BSTG): I WAS there to experience and saw the decay of transparency and more; it takes courage, resolve and patience to stay the course of asking the questions without response!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider their investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in FATE, CRS, securities referred to in this publication.
